MEDSHealthcare · Medical Distribution

MEDS Stock Forecast: DataMeds AI, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$3.76

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 19 Sept 2026 — in the weakest quartile.

Market cap

$11.5M

Ticker Nerd rank

16 / 100

Median analyst target

—

Analysts covering

Revenue$1.8M−77.2% y/y

Operating income−$7.3M

Net income−$18.4M

Free cash flow−$3.1M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

MEDS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DataMeds AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Growth

Volatility

Revisions

Momentum

Value

Quality

Issuance

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MEDS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MEDS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
1 June 2023	EF Hutton	Assumes	Buy	$1.25
16 May 2023	EF Hutton	Maintains	Buy	$1.70 → $1.25
28 Mar 2023	Maxim Group	Maintains	Buy	$2.50 → $1.75
9 Dec 2021	EF Hutton	Initiates	Buy	$4.50
3 Dec 2020	National Securities	Initiates	Buy	—
3 Dec 2020	National Securities Corporation	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MEDS appears on the weeks it earns a place.

Estimates

MEDS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

DataMeds AI, Inc. (MEDS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.1×
Price / sales: 1.5×
Price / book: −0.5×
EV / EBITDA: −0.8×

Growth & margins

Revenue growth (YoY): −77.2%
Earnings growth (YoY): −77.2%
Gross margin: 10.2%
Operating margin: −412.7%
Net margin: −27.5%

Returns & dividend

Return on equity: 813.6%
Return on assets: −82.9%
Dividend yield: 158.7%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DataMeds AI, Inc. (MEDS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

DataMeds AI, Inc. has a market value of $11.5M and an enterprise value of $41.7M.
Revenue in the twelve months to 30 June 2026: $8.0M. The latest quarter shrank 77.2% year on year.
Net income over the same four quarters: −$88.3M, a −1100.3% net margin.
Free cash flow in the twelve months to 30 June 2026: −$14.7M.
Shares outstanding: 2.8M.
Trailing P/E: −0.1×; forward P/E: −16.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 158.73%, paying out 0% of earnings.
DataMeds AI, Inc. employs 8 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Sept 2026

Data provided by Twelve Data

Peers

MEDS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution

Company	Market cap	TKN rank
MEDSDataMeds AI, Inc.	$11.5M	16
COSMCosmos Health, Inc.	$32.0M	18
ACHAccendra Health, Inc.	$68.7M	44
SNYRSynergy CHC Corp.	$1.3M	—
MTVAMetaVia, Inc.*	$11.4M	18
IRIXIRIDEX Corp.*	$11.5M	78
BMRABiomerica, Inc.*	$11.5M	16

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DataMeds AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MEDS news & analysis

DataMEDS AI Unveils New Corporate Website

Accesswire · 21 Sept 2026positive

DataMEDS AI, Inc. announced the launch of its new corporate website, www.DataMedsAI.com, which aligns with pending marketing initiatives. This follows the company's recent acquisition of Helomics Corporation's AI Cancer Diagnostics Lab from Axe Compute and the settlement of outstanding litigation that extinguished roughly $19 million in liabilities and retired 364,099 common shares.

Why it matters — A MEDS watcher would care because the website launch reflects the company's ongoing strategic repositioning after the Helomics acquisition and the litigation settlement that strengthened its balance sheet and reduced its share count.

DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked

Accesswire · 18 Sept 2026positive

DataMeds AI announced it settled litigation tied to the May 2023 Wellgistics Membership Purchase Interest Agreement, extinguishing roughly $19 million in balance-sheet liabilities. As part of the settlement, the company retired approximately 364,099 shares of its common stock.

Why it matters — A MEDS watcher would care because the settlement removes roughly $19 million in liabilities and reduces the share count, though it resolves obligations related to a prior acquisition agreement.

This AI stock experienced a 5x rally on Wednesday

Invezz · 16 Sept 2026positive

DataMeds AI (MEDS) shares surged on Wednesday as the company completed its acquisition of Helomics AI, a cancer diagnostics laboratory and precision oncology contract research organization. The stock rose above its key moving averages, accelerating its upward momentum on September 16.

Why it matters — The completed acquisition of Helomics AI represents a transformative expansion of MEDS' capabilities in cancer diagnostics and precision oncology, which drove a sharp rise in the stock.

DataMEDS AI Stock Surges Wednesday: What's Driving the Action?

Benzinga · 16 Sept 2026positive

Shares of DataMEDS AI Inc. (NASDAQ:MEDS) traded sharply higher Wednesday morning as investors reacted to the completed acquisition of an AI-driven cancer diagnostics platform and contract research organization business.

Why it matters — The completed acquisition of an AI-driven cancer diagnostics platform and contract research organization business marks a notable expansion milestone that MEDS watchers would follow closely.

DataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe Compute

Accesswire · 15 Sept 2026neutral

DataMEDS AI, Inc. announced it completed the acquisition of Helomics Corporation, Axe Compute Inc.'s artificial intelligence cancer diagnostics laboratory subsidiary, in exchange for DataMEDS common shares and an acquisition note totaling $1.5 million. The acquisition is intended to provide operational capital to support the company's Health Lives Here campaign and expand its services into cancer management.

Why it matters — A MEDS watcher would care because this acquisition expands DataMEDS' service offerings into cancer management and introduces AI-based cancer diagnostics capabilities to its vertically integrated health data business.

FAQ

Frequently asked questions about MEDS stock

How does Ticker Nerd's model rank MEDS?

As at 19 Sept 2026, DataMeds AI, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

What is the MEDS stock forecast for 2030?

No analyst covering DataMeds AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDS are extrapolating price history, which says nothing about the business.

What does DataMeds AI, Inc. do?

DataMeds AI Inc. is a healthcare technology and pharmaceutical logistics company that focuses on integrating pharmacy operations, digital health infrastructure, and health information tools.

What is the latest news on MEDS?

The most recent item we track (Accesswire, 21 Sept 2026): "DataMEDS AI Unveils New Corporate Website". DataMEDS AI, Inc. announced the launch of its new corporate website, www.DataMedsAI.com, which aligns with pending marketing initiatives. This follows the company's recent acquisition of Helomics Corporation's AI Cancer Diagnostics Lab from Axe Compute and the settlement of outstanding litigation that extinguished roughly $19 million in liabilities and retired 364,099 common shares.

Company

About DataMeds AI, Inc.

DataMeds AI Inc. is a healthcare technology and pharmaceutical logistics company that focuses on integrating pharmacy operations, digital health infrastructure, and health information tools. The company provides technology-driven solutions that support prescription fulfillment, pharmacy coordination, clinical services, and healthcare data workflows across the drug supply chain. Its current platform combines artificial intelligence and blockchain-enabled smart contract capabilities to streamline interactions among pharmacies, providers, manufacturers, and payors. DataMeds AI also operates across pharmacy services, wholesale distribution, and telemedicine-adjacent business units, with an emphasis on improving access, transparency, and operational efficiency in healthcare delivery. The company serves as a bridge between clinical care and pharmaceutical commerce, positioning its products and services within the broader health IT and pharmaceutical services markets.

CEO Mr. Prashant Patel M.Sc., R.Ph. · 8 employees · United States · https://datamedsai.com